Axsome Therapeutics
$72.299876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$72.29
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.37 (+1.93%) Today
$0.00 (0.00%) As of 8:00 PM EST after-hours
Why Robinhood?
You can buy or sell AXSM and other stocks, options, and ETFs commission-free!
About AXSM
Axsome Therapeutics, Inc. Common Stock, also called Axsome Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY. The listed name for AXSM is Axsome Therapeutics, Inc. Common Stock.
CEO
Herriott Tabuteau
Employees
45
Headquarters
New York, New York
Founded
2012
Market Cap
2.70B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
298.06K
High Today
$73.16
Low Today
$69.50
Open Price
$71.73
Volume
249.61K
52 Week High
$109.94
52 Week Low
$33.45
Collections
Analyst Ratings
91%
of 11 ratings
Buy
91%
Hold
0%
Sell
9%
AXSM Earnings
-$0.88
-$0.59
-$0.29
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, Pre-Market